SEC Tracker
Get the app

Palvella Therapeutics PVLA

Palvella Therapeutics: ends a material agreement, reports quarterly results and 2 other items

Form
8-K
Filed
Importance
Routine
  • Ends a material agreement (1.02)
  • Reports quarterly results (2.02)
  • Announces exit or restructuring costs (2.05)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Palvella Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Esperion Therapeutics ESPR public float $198M, Jun 30, 2025
  2. Editas Medicine EDIT public float $191M, Jun 30, 2025
  3. Rezolute RZLT public float $204M, Dec 31, 2025
  4. Cardiff Oncology CRDF public float $205M, Jun 30, 2025
  5. Silence Therapeutics SLN public float $206M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.